Roche Strengthens Cancer Vaccine R&D With $1B immatics Deal
This article was originally published in The Pink Sheet Daily
Combining immatics’ tumor-associated peptide vaccines with Roche’s checkpoint inhibitors is expected to provide a promising approach to the development of novel combination immunotherapies.
You may also be interested in...
With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.
“Cancer immunology will play a far greater role than it ever has within the [Roche Pharma Research and Early Development Organization] and we hope there will be synergies we can exploit with other treatment modalities under development at Roche,” Levitsky says.
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.